REAL-WORLD DATA ANALYSIS OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATMENT DECISIONS WITH THE INTRODUCTION OF NEWER TREATMENT OPTIONS

被引：0
|
作者：
Scott, J. [1 ]
Concepcion, R. [1 ]
Garofalo, D. [1 ]
Verma-Kurvari, S. [1 ]
Xu, B. [1 ]
Montgomery, J. [1 ]
机构：
[1] Integra Connect, W Palm Beach, FL USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.246
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN199
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [1] Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US
    Shore, N.
    Laliberte, F.
    Ionescu-Ittu, R.
    Gayle, A.
    Amin, S.
    Yang, L.
    Payne, S.
    Mahendran, M.
    Lejeune, D.
    Yu, L.
    Burgents, J.
    Duh, M. S.
    Ghate, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S534 - S535
  • [2] Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
    Malangone-Monaco, Elisabetta
    Li, Weiyan
    Noxon, Virginia
    Jiang, Shan
    Amin, Suvina
    Ghate, Sameer
    Swami, Umang
    Agarwali, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Treatment evolution for metastatic castration-resistant prostate cancer (mCRPC) with recent introduction of new oral agents: Retrospective analysis of real world data
    Flaig, Thomas W.
    Potluri, Ravi C.
    Ng, Yvette
    Todd, Mary Beth
    Mehra, Maneesha
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data
    Flaig, Thomas W.
    Potluri, Ravi C.
    Ng, Yvette
    Todd, Mary B.
    Mehra, Maneesha
    CANCER MEDICINE, 2016, 5 (02): : 182 - 191
  • [5] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [6] Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Lumen, Nicolaas
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    van den Berg, Erik
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
    Morgans, A. K.
    Divan, H. A.
    Birtle, A. J.
    Dorff, T.
    Ozatilgan, A.
    Graff, J. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 334 - 334
  • [10] Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population.
    Freedland, Stephen J.
    Davis, Matthew
    Epstein, Andrew J.
    Arondekar, Bhakti
    Ivanova, Jasmina I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 406 - 406
12345